Several exciting pre-clinical and clinical studies are imminent. We are therefore happy that we have been able to recruit two very experienced and competent Scientists. Dr William Stafford has taken up the position as Translational Director from 1st of September. He will reinforce the Oxcia team with his background in oncology and redox biology, drug discovery and business development. In addition, Sandra Ekstedt has joined Oxcia as Senior Scientist and will primarily support the work with OXC-201, Oxcias promising project for Idiopathic pulmonary fibrosis (IPF). She adds special expertise in inflammatory cells and their involvement in diseases. With a new collaboration agreement with Karolinska Institutet (KI) on investigating the role of the repair enzyme OGG1 in IPF and the underlying mechanism of action of OXC-201, Sandra will work very closely with KI.
“We are very happy for this reinforcement to the team and are looking forward to strengthening the collaboration with KI on OXC-201 science”, says Christina Kaldéren, Preclinical Director Oxcia.
